drugset / Trial / NCT05808582
Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+ABC
Timeline
- Start
- 2023-05-01
- Primary completion
- 2023-09-01
- Completion
- 2024-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Tucidinostat | Small molecule | — | — |